Group 1 - The high-pressure oxygen chamber concept declined by 1.90% as of the market close on September 22, ranking among the top declines in concept sectors, with companies like Hangzhou Oxygen, Innovative Medical, and China Railway Construction showing significant drops [1] - The high-pressure oxygen chamber sector experienced a net outflow of 238 million yuan from main funds today, with seven stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows. Innovative Medical led with a net outflow of 126 million yuan, followed by China Railway Construction and Hangzhou Oxygen [2] - The top stocks with net outflows in the high-pressure oxygen chamber sector included Innovative Medical (-4.18%), China Railway Construction (-2.36%), and Hangzhou Oxygen (-4.56%), with respective main fund outflows of 126.14 million yuan, 53.78 million yuan, and 21.64 million yuan [2] Group 2 - The concept sectors with the highest gains today included Tonghuashun Fruit Index (+5.17%), AI Mobile Phones (+4.06%), and Smart Speakers (+3.43%), while the high-pressure oxygen chamber sector was among the top decliners [2] - The main fund inflows were observed in stocks like Jinling Pharmaceutical, Weiao Co., and Dahu Co., with inflows of 2.58 million yuan, 1.16 million yuan, and 0.95 million yuan respectively [2]

Group 1 - The article highlights the significant impact of technology on the agricultural sector in Guangdong, particularly focusing on the edible mushroom industry in Shaoguan, which is referred to as the "Mushroom Capital of Guangdong" [2] - Shaoguan's Qujiang District produces up to 180 tons of fresh mushrooms daily, with an annual output exceeding 50,000 tons, accounting for 60% of the market share in Guangdong [2] - Xinghe Biotechnology Co., Ltd., a leading company in Shaoguan's edible mushroom industry, utilizes advanced techniques such as molecular markers, hybridization, and purification to cultivate high-yield and uniquely flavored mushroom strains, establishing a standardized breeding system with over 20 varieties [2] Group 2 - The article is part of a series titled "Yue Lai Yue Hao," which showcases 100 agricultural technology application scenarios, covering themes such as seed industry revitalization, marine ranching, new agricultural machinery, smart farms, ecological agriculture, and digital production and sales [2] - The collaborative effort involves the Guangdong Provincial Department of Agriculture and Rural Affairs, the Guangdong Provincial Department of Science and Technology, and the Guangdong Academy of Sciences, aiming to demonstrate how technology injects new momentum into agriculture [2]

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a significant increase in stock price and trading activity, indicating positive market sentiment despite recent fluctuations [1][2] - As of September 19, Yingkang Life's stock price rose by 2.08% to 11.76 CNY per share, with a total market capitalization of 8.814 billion CNY [1] - The company has experienced a year-to-date stock price increase of 27.83%, with a recent decline of 8.55% over the last five trading days [1] Group 2 - Yingkang Life, established on August 6, 1998, and listed on December 9, 2010, is based in Qingdao, Shandong Province, and specializes in medical devices and services [2] - The company's main business segments include the development, production, and sales of medical equipment, particularly focusing on cancer treatment technologies [2] - As of September 10, the number of shareholders increased by 22.06% to 24,500, while the average circulating shares per person decreased by 18.07% to 26,191 shares [2] Group 3 - Yingkang Life reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit of 61.83 million CNY, up 12.82% year-on-year [2] - The company has distributed a total of 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Market Overview - On September 18, the medical services sector declined by 1.68%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - Notable gainers included: - Zenggansi (301257) with a closing price of 53.80, up 6.89% [1] - Yangguang Nuohuo (688621) at 79.58, up 1.38% [1] - Kanglong Huacheng (300759) at 35.70, up 0.59% [1] - Major decliners included: - Nanmo Biology (688265) at 56.16, down 5.93% [2] - Chuangxin Medical (002173) at 23.48, down 4.75% [2] - Hongbo Pharmaceutical (301230) at 36.12, down 4.06% [2] Capital Flow - The medical services sector experienced a net outflow of 2.099 billion yuan from institutional investors, while retail investors saw a net inflow of 1.474 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment among different investor types [2] Individual Stock Capital Flow - Notable capital flows included: - Huada Gene (300676) with a net inflow of 63.2761 million yuan from institutional investors [3] - Baicheng Pharmaceutical (301096) with a net inflow of 21.5534 million yuan from institutional investors [3] - Nanmo Biology (688265) saw a net outflow of 1.597 million yuan from institutional investors [3]

证券日报网讯盈康生命（300143）9月12日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东总数为24，487户。 ...

证券日报网讯 盈康生命9月12日发布公告，在公司回答调研者提问时表示，公司持续践行"质量放心、 服务暖心、环境舒心"的"三心"标准，从新场景、新技术、新体验等方面满足患者差异化需求，打造社 会资本办医服务第一联想度。围绕新场景、新体验，公司上半年增加减重门诊等新场景，提供全周期体 重管理服务；基于基因技术提供精准抗衰方案；创新一站式门诊服务中心，打造行业示范效应。公司引 进新特药100余种，旗下友谊医院获批区域内首家国际医疗旅游试点示范基地，托管的永慈医院打造"疗 愈花园"，给用户带来全新体验。围绕新技术，公司持续落地创新应用，迭代解决方案100余项，持续提 升临床诊疗水平。上半年公司在消化内科、骨科、妇科等多个科室引入知名专家，同时引入多项行业领 先技术、术式，涵盖肿瘤、心血管、胸外、消化内科、泌尿外科等专科。 （编辑 王雪儿） ...

证券代码：300143 证券简称：盈康生命 投资者关系活动记录表 编号：2025-07 投资者关 系活动类 别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 （电话会议） 参与单位 名称及人 员姓名 南方基金 冯啸 秦乾一 张德曦 陈哲、东证资管 邹秉昂、华创自营 胡建东、易米基金 刘家曦、中泰证券 祝嘉琦 孙宇瑶 余燕伶、平 安证券 裴晓鹏、光大证券 吴佳青、中信证券 沈睦钧 王凯 时间 2025 年 9 月 11 日 地点 山东省青岛市崂山区海尔路 1 号盈康一生大厦 18 楼盈康生命科 技股份有限公司会议室 上市公司 接待人员 姓名 董事会秘书 刘泽霖 投资者关系总监 董丁梦 投资者关 系活动主 要内容介 绍 1、公司在 AI 医疗方面有比较长时间和广泛的布局，请具体介 绍下，以及从经营数据上看有哪些提升效果？ 回答：公司AI应用经历了1.0 阶段（统一整合旗下医院四大核 心系统，实现一体化整合，解决信息孤岛等问题）、2.0 阶段（建 设互联网医院平台，构建"线上+ 线下"一体化服务链，建设大数 据湖，搭建医院管理自日清平台）和AI 应用3.0 阶 ...

证券日报网讯盈康生命（300143）9月10日在互动平台回答投资者提问时表示，根据2025年半年报，高 新区产业园建设项目工程进度69.18%。公司托管医院上海永慈康复医院联合生态方傅利叶共同打造了 国内领先的康复机器人物联港，若有达到信息披露标准的相关事项，将严格按照规定及时履行信息披露 义务。 ...

银河康乐股票A（519673）基金经理为方伟。 资料显示，盈康生命科技股份有限公司位于山东省青岛市崂山区海尔路1号盈康一生大厦17楼，成立日 期1998年8月6日，上市日期2010年12月9日，公司主营业务涉及医疗器械及医疗服务,其中医疗器械板块 主要为研发、生产、销售玛西普数控放疗设备、玛西普伽玛刀及其它大型医疗设备,医疗软件开发;公司 医疗服务板块主要为围绕肿瘤预防、诊断、治疗及康复业务,通过新建和收购方式进行医院布局,建立肿 瘤专科医院线下医疗服务体系,构建上下联动的肿瘤服务网络,打造国内领先的专业肿瘤放射治疗服务平 台。主营业务收入构成为：医疗服务77.47%，其中:设备及耗材22.53%，医疗器械22.53%。 从基金十大重仓股角度 数据显示，银河基金旗下1只基金重仓盈康生命。银河康乐股票A（519673）二季度增持18.4万股，持有 股数93.09万股，占基金净值比例为5.06%，位居第六大重仓股。根据测算，今日浮盈赚取约58.65万 元。 银河康乐股票A（519673）成立日期2014年11月18日，最新规模1.55亿。今年以来收益34.53%，同类排 名964/4222；近一年收益60.7%， ...

国泰海通证券股份有限公司 关于盈康生命科技股份有限公司 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1. 公司信息披露审阅情况 | | | (1)是否及时审阅公司信息披露文件 | 是 | | (2)未及时审阅公司信息披露文件的次数 | 0 次 | | 2. 督导公司建立健全并有效执行规章制度的情况 | | | (1)是否督导公司建立健全规章制度(包括但不限于防 止关联方占用公司资源的制度、募集资金管理制度、内 | 是 | | 控制度、内部审计制度、关联交易制度) (2)公司是否有效执行相关规章制度 | ル | | 3. 募集资金监督情况 | | | (1)查询公司募集资金专户次数 | 每月1次,共6次 | | (2)公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4. 公司治理督导情况 | | | (1) 列席公司股东会次数 | 0 次,已审阅相关会议文件 | | (2)列席公司董事会次数 | 0 次,已审阅相关会议文件 | | (3)列席公司监事会次数 | 0次,已审阅相关会议文件 | | 5. 现场检查情况 | | | (1)现场检查次数 | 0 次,计划下半 ...